Dr. Xinyu Bi 毕新宇
Chief Physician
Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of liver cancer, hilar cholangiocarcinoma, periampullary cancer, gallbladder cancer, cholangiocarcinoma, and colorectal liver metastases.
Dr. Bi is a Chief Physician and doctoral supervisor specializing in the diagnosis and surgical treatment of liver and biliary diseases. Research focuses on comprehensive, surgery-based treatment of hepatobiliary tumors, particularly biliary tract tumors, prevention of postoperative recurrence, and management of colorectal liver metastases. Dr. Bi has led or participated in 15 national and provincial projects and published over 60 papers.
Professional roles
- Member, Biliary Tract Group, Surgery Branch, Chinese Medical Association
- Secretary, Liver Cancer Quality Control Expert Committee, National Cancer Center/National Tumor Quality Control Center
- Standing Committee Member and Secretary-General, Sarcoma Professional Committee, China Anti-Cancer Association
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Bi Xinyu). Papers usually list the name as Xinyu Bi or Bi X.
Selected publications
15 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2025 (senior author): Systemic immune-inflammation index: a key biomarker guiding personalized adjuvant chemotherapy in intrahepatic cholangiocarcinoma. PubMed 41244904
- Sci Rep, 2025 (senior author): Efficacy and safety of anlotinib monotherapy for advanced hepatocellular carcinoma and clinical role of α-fetoprotein. PubMed 40783436
- Liver Cancer, 2025 (first author): Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma. PubMed 40547962
- Liver Cancer, 2025 (first author): Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update. PubMed 40255878
- Cancer Cell Int, 2024 (senior author): MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1. PubMed 38582841
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion